IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
British Journal of Cancer.
Times cited: 21
Hyperbilirubinemia in pazopanibor sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.
Annals of Oncology.
Times cited: 14